Article Text
Statistics from Altmetric.com
One-third of preterm infants are diagnosed with bronchopulmonary dysplasia (BPD), a complex multifactorial disorder associated with significant morbidity. Associated pathologies include pulmonary hypertension (PH), a critical cardiorespiratory pathology with 48% 2-year mortality that affects up to a third of infants with BPD.1 Pulmonary vasodilatation in PH prolongs life, and phosphodiesterase-V inhibition is the primary approach for this.2 That stated, current evidence is limited to 45 patients across five case series.3 They demonstrate a reduction in overall mortality to 18%, but reservations remain regarding safety and efficacy.
We therefore conducted a retrospective investigation into patients with BPD–PH managed at our centre between August 2008 and July …
Footnotes
-
Contributors All authors made substantial contributions to the conception of the work and the acquisition, analysis or interpretation of data; drafted the work and approved the version submitted for publication.
-
Competing interests None.
-
Provenance and peer review Not commissioned; internally peer reviewed.